Medication info
Linaone Duo Tablets 2.5/1000 mg (Linagliptin, Metformin)

Linaone Duo Tablets 2.5/1000 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Hana Pharm Co., Ltd.
Appearance
Bright pink, oval, film-coated tablet with a double convex surface
Packaging
30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 201903532 · Approved 2019.05.29 · Insurance code 657808100

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy whose blood glucose cannot be adequately controlled with monotherapy, the initial dose is 1 tablet of this drug 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this drug 2.5/1000 mg twice daily. 2. Patients whose blood glucose cannot be adequately controlled with metformin monotherapy: The initial dose of this drug should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s previous metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start at their previous doses of linagliptin and metformin. 4. Patients whose blood glucose cannot be adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this drug should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s previous metformin dose. When this drug is administered in combination with a sulfonylurea, the sulfonylurea dose may need to be reduced to lower the risk of hypoglycemia (see Precautions, 3. Administration with caution in the following patients). 5. Patients whose blood glucose cannot be adequately controlled with combination therapy with insulin and metformin: The initial dose of this drug should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s previous metformin dose. When this drug is administered in combination with insulin, the insulin dose may need to be reduced to lower the risk of hypoglycemia (see Precautions, 3. Administration with caution in the following patients). No studies have evaluated the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate [eGFR] 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis. Treatment should not be initiated with this drug because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Hana Pharm Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used alongside diet and exercise to help patients with type 2 diabetes manage their blood glucose levels. The combination of linagliptin and metformin effectively manages blood sugar, helping to maintain healthy blood glucose levels. Therefore, it serves as a suitable therapeutic adjunct for those struggling to control their blood sugar.

How to take

Adult dose

The dose of this drug should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy whose blood glucose cannot be adequately controlled with monotherapy, the initial dose is 1 tablet of this drug 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this drug 2.5/1000 mg twice daily. 2. Patients whose blood glucose cannot be adequately controlled with metformin monotherapy: The initial dose of this drug should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s previous metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start at their previous doses of linagliptin and metformin. 4. Patients whose blood glucose cannot be adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this drug should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s previous metformin dose. When this drug is administered in combination with a sulfonylurea, the sulfonylurea dose may need to be reduced to lower the risk of hypoglycemia (see Precautions, 3. Administration with caution in the following patients). 5. Patients whose blood glucose cannot be adequately controlled with combination therapy with insulin and metformin: The initial dose of this drug should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s previous metformin dose. When this drug is administered in combination with insulin, the insulin dose may need to be reduced to lower the risk of hypoglycemia (see Precautions, 3. Administration with caution in the following patients). No studies have evaluated the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate [eGFR] 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis. Treatment should not be initiated with this drug because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Do not administer to the following patients).

Precautions

This medication is used for the treatment of diabetes and contains two active ingredients that assist with blood glucose control. When taking this medication, rare side effects such as lactic acidosis may occur; hence, patients with impaired kidney function or liver problems should exercise particular caution. This medication should not be administered to certain patients, such as those with type 1 diabetes, severe kidney impairment, or acute myocardial infarction or severe infections. Additionally, it is safe for pregnant or breastfeeding women to avoid using this medication. When using this medication with other hypoglycemic agents, patients should frequently monitor their blood glucose levels due to the risk of hypoglycemia, and may need to adjust dosages of other medications if necessary. Seniors with reduced kidney function should undergo regular kidney function tests and use appropriate adjusted dosages. Patients facing acute illnesses or approaching surgery should temporarily discontinue this medication, and can resume it once kidney function is confirmed normal after tests or treatments. If symptoms such as abdominal pain, severe muscle pain, fatigue, or shortness of breath occur during the treatment, immediate consultation with a physician is required, especially in cases of acute pancreatitis or skin blistering, which should also result in immediate discontinuation and consultation with an expert. Furthermore, prolonged use may lead to vitamin B12 deficiency; therefore, patients should be tested for vitamin B12 levels if experiencing anemia or neurological symptoms. This medication can interact with multiple drugs; therefore, patients taking other medications must inform their doctor or pharmacist and be closely monitored. For children under 10 years old or adolescents aged 10-17, safety and efficacy have not been established, hence its use is not recommended. Finally, this medication should be stored out of reach of children and in a place free from moisture and direct sunlight.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • taste disturbances
  • cough
  • decreased appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
Show 132 more
  • abdominal pain
  • formation of oral ulcers
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rashes
  • bullous pemphigoid-like
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • oral ulcers
  • hepatitis
  • rashes
  • pruritus
  • abdominal pain
  • vomiting
  • diarrhea
  • decreased appetite
  • constipation
  • oral ulcers
  • abnormal liver function tests
  • hepatitis
  • erythema
  • bullous pemphigoid-like
  • severe arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • dysarthria
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone bruise
  • concussion
  • bone fracture
  • hand fracture
  • itching
  • hypertension
  • benign prostatic hyperplasia
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • pancreatitis
  • stomatitis
  • mediastinitis
  • pneumonia
  • rhinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyps
  • dyspepsia
  • anal bleeding
  • cheilitis
  • cavities
  • enteritis
  • gastritis
  • stomatitis
  • dizziness
  • drowsiness
  • chest discomfort
  • asthenia
  • nosebleed
  • oropharyngeal pain
  • voice disorder
  • epistaxis
  • hearing loss
  • erectile dysfunction
  • goiter
  • confusion
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is best to maintain a storage temperature between 1 and 30 degrees Celsius. This will help maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Bright pink, oval, film-coated tablet with a double convex surface

Package unit

30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.